Carlos L. Arteaga is in the Departments of Medicine and Cancer Biology and Breast Cancer Program, Vanderbilt-Ingram Comprehensive Cancer Center and Vanderbilt University School of Medicine, Nashville, Tennessee, USA. carlos.arteaga@vanderbilt.edu
Two clinical studies have identified mutations affecting the EGF receptor in lung cancers from patients who respond robustly to gefitinib, a small-molecule inhibitor of the receptor tyrosine kinase. This work highlights the importance of conducting clinical trials with an eye to delivering molecule-targeted therapeutics to those patients most likely to benefit.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
